Suppr超能文献

骨骼肌钙释放通道(兰尼碱受体)中载脂蛋白钙调蛋白及Ca2+ -钙调蛋白调节域的鉴定。

Identification of apocalmodulin and Ca2+-calmodulin regulatory domain in skeletal muscle Ca2+ release channel, ryanodine receptor.

作者信息

Yamaguchi N, Xin C, Meissner G

机构信息

Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, North Carolina 27599-7260, USA.

出版信息

J Biol Chem. 2001 Jun 22;276(25):22579-85. doi: 10.1074/jbc.M102729200. Epub 2001 Apr 16.

Abstract

Fusion proteins and full-length mutants were generated to identify the Ca(2+)-free (apoCaM) and Ca(2+)-bound (CaCaM) calmodulin binding sites of the skeletal muscle Ca(2+) release channel/ryanodine receptor (RyR1). [(35)S]Calmodulin (CaM) overlays of fusion proteins revealed one potential Ca(2+)-dependent (aa 3553-3662) and one Ca(2+)-independent (aa 4302-4430) CaM binding domain. W3620A or L3624D substitutions almost abolished completely, whereas V3619A or L3624A substitutions reduced [(35)S]CaM binding to fusion protein (aa 3553-3662). Three full-length RyR1 single-site mutants (V3619A,W3620A,L3624D) and one deletion mutant (Delta4274-4535) were generated and expressed in human embryonic kidney 293 cells. L3624D exhibited greatly reduced [(35)S]CaM binding affinity as indicated by a lack of noticeable binding of apoCaM and CaCaM (nanomolar) and the requirement of CaCaM (micromolar) for the inhibition of RyR1 activity. W3620A bound CaM (nanomolar) only in the absence of Ca(2+) and did not show inhibition of RyR1 activity by 3 microm CaCaM. V3619A and the deletion mutant bound apoCaM and CaCaM at levels compared with wild type. V3619A activity was inhibited by CaM with IC(50) approximately 200 nm, as compared with IC(50) approximately 50 nm for wild type and the deletion mutant. [(35)S]CaM binding experiments with sarcoplasmic reticulum vesicles suggested that apoCaM and CaCaM bind to the same region of the native RyR1 channel complex. These results indicate that the intact RyR1 has a single CaM binding domain that is shared by apoCaM and CaCaM.

摘要

构建融合蛋白和全长突变体,以鉴定骨骼肌钙释放通道/雷诺丁受体(RyR1)的无钙(脱钙钙调蛋白,apoCaM)和钙结合(钙-钙调蛋白,CaCaM)钙调蛋白结合位点。融合蛋白的[³⁵S]钙调蛋白(CaM)覆盖实验揭示了一个潜在的钙依赖性(氨基酸3553 - 3662)和一个钙非依赖性(氨基酸4302 - 4430)CaM结合结构域。W3620A或L3624D替换几乎完全消除了结合,而V3619A或L3624A替换降低了[³⁵S]CaM与融合蛋白(氨基酸3553 - 3662)的结合。构建了三个全长RyR1单点突变体(V3619A、W3620A、L3624D)和一个缺失突变体(Δ4274 - 4535),并在人胚肾293细胞中表达。L3624D表现出显著降低的[³⁵S]CaM结合亲和力,表现为脱钙钙调蛋白和钙-钙调蛋白(纳摩尔级)缺乏明显结合,以及抑制RyR1活性需要微摩尔级的钙-钙调蛋白。W3620A仅在无钙时结合CaM(纳摩尔级),并且3微摩尔钙-钙调蛋白未显示对RyR1活性的抑制。V3619A和缺失突变体与野生型相比,结合脱钙钙调蛋白和钙-钙调蛋白的水平相当。与野生型和缺失突变体的IC₅₀约50纳米相比,V3619A的活性被CaM抑制,IC₅₀约为200纳米。肌浆网囊泡的[³⁵S]CaM结合实验表明,脱钙钙调蛋白和钙-钙调蛋白结合到天然RyR1通道复合物的同一区域。这些结果表明,完整的RyR1具有一个单一的CaM结合结构域,脱钙钙调蛋白和钙-钙调蛋白共享该结构域。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验